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Amyotrophic lateral sclerosis (ALS)–motor neuron disease (MND) is divisible into 6 familial and 
10 sporadic syndromes (1). Familial syndromes are also recognized in animals, namely, dogs, cattle, 
rats, and mice. This article is concerned with the most common form of ALS, sporadic Charcot ALS 
(SC-ALS). This form is of particular interest because it does not occur in any animal as a complete 
disease; instead, each of its three parts can occur as separate syndromes in sheep, horses, and cats. 
It is possible that physiological differences between these animals and humans could explain this 
separation. In addition, an understanding of the etiology of each animal syndrome could reveal a 
common predisposing factor that is responsible for generating the complete disease. Molybdenum 
(Mo) deficiency has recently been demonstrated as the predisposing factor for two of the animal 
syndromes and the third has a pathogenesis that is consistent with Mo deficiency. This raises the 
possibility that Mo deficiency is the predisposing factor for SC-ALS.
Two of the three animal syndromes referred to occur in sheep and are associated with Mo defi-
ciency. Both produce specific motor nervous effects not known to occur in any other sporadic, adult 
onset, animal disorder. The first is xanthosine motor neuron syndrome (XMNS) (2). In this chroni-
cally progressive and irreversible syndrome, an asymmetric muscle weakness develops in one pelvic 
limb and sometime later, in the corresponding thoracic limb. The muscle weakness is accompanied 
by atrophy, and dysfunction is restricted to particular extensor muscles. The commonest presenta-
tion of SC-ALS is similar to this and involves asymmetric weakness and atrophy of some muscle 
groups in either upper or lower limb. Asymmetric muscle weakness in mammals is produced by a 
very precise upper motor dysfunction that can only emanate from the basal ganglia in animals, such 
as sheep, and from the basal ganglia and motor cortex in humans (3–5). Xanthosine ingestion during 
Mo deficiency is the only etiology so far demonstrated in a mammal, which can produce this type of 
progressive and irreversible asymmetric muscle weakness.
The second Mo deficiency-associated sheep disorder is inosine motor neuron syndrome (IMNS) 
(6). In this chronically progressive and irreversible syndrome, a brain stem-generated bulbar muscle 
weakness develops together with a brain stem-generated respiratory muscle weakness. These two 
dysfunctions lead to difficulty in vocalizing, swallowing, and breathing, including a reduced forced 
vital capacity.
In SC-ALS, 30% of cases present with bulbar signs and in the remaining 70% bulbar signs usually 
develop during the course of the disease. Bulbar involvement in SC-ALS is often closely correlated 
with respiratory muscle weakness, including reduced forced vital capacity (1).
Inosine ingestion during Mo deficiency is the only etiology so far demonstrated in a mammal, 
which can produce this type of progressive and irreversible muscle weakness. The lingual, laryngeal, 
and pharyngeal muscle dysfunctions that cause the bulbar effects can be generated by either abnor-
mal upper motor control over the hypoglossal nuclei in the medulla or by abnormal functioning of 
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the hypoglossal nuclei themselves. The diaphragm and intercos-
tal muscle dysfunction that causes the respiratory effect can be 
generated in two different ways: first, via abnormal upper motor 
control over the pontomedullary respiratory center, which then 
affects the phrenic nerve neurons in the cervical spine; or sec-
ond, via abnormal activity of the cervical phrenic nerve neurons 
themselves. In IMNS, the former is the case, whereas, in SC-ALS, 
it is more likely that that the former occurs first but the latter 
develops later on.
The third part of SC-ALS that occurs in animals has only been 
observed in horses (7) and cats (8). It is referred to as equine 
and feline MND, respectively. Both appear to be clinically and 
pathologically similar but much more is known about the former 
(EMND) than the latter. EMND is a sporadic, idiopathic, lower 
MND. It occurs in adult horses that have been eating an unbal-
anced diet for over 12 months or more. Similar to SC-ALS, this 
disease is characterized by the development of profound, bilater-
ally symmetrical muscle weakness, atrophy, and fasciculations, 
which affect the head, neck, axial skeleton, and limbs.
In EMND, these motor nervous effects are caused by the 
degeneration of the lower motor neuron affiliated neurons in the 
brain stem and the spinal motor neurons in the ventral (anterior) 
horns. In SC-ALS similar effects occur and are caused by the 
same neuronal degeneration. It is noteworthy that in EMND 
there is no report of asymmetric limb muscle weakness, bulbar 
muscle weakness, or respiratory muscle weakness. The cause of 
EMND is thought to be dietary but no specific imbalance has 
been demonstrated, so far. Low levels of the antioxidant, vitamin 
E, are frequently identified in affected horses (9, 10). Based on the 
reasoning that follows, Mo deficiency could be the predisposing 
factor for this disorder and presumably for that part of SC-ALS 
that equates with it.
Molybdenum deficiency predisposes mammals to CNS disease 
because it inactivates both xanthine oxidase-dehydrogenase (the 
enzyme barrier that protects the CNS from dietary purine load-
ing) and sulfite oxidase (the enzyme barrier that protects the CNS 
from dietary sulfite loading). Mo is an essential cofactor for these 
two enzymes. XMNS and IMNS are caused by purine loading, 
and EMND could potentially be caused by sulfite loading. Dietary 
sources of the purine nucleosides xanthosine, inosine, adenosine, 
and guanosine, and their bases xanthine, hypoxanthine, adenine, 
and guanine, respectively, can cause purine loading, and dietary 
sources of sulfur amino acids can cause sulfite loading. Purine 
loading leads to astrocyte degeneration (2, 6), and this adversely 
affects normal astrocytic modulation of neurotransmission. 
Sulfite loading blocks the normal conversion of methionine to 
cysteine, and this causes homocysteine values to rise and cysteine 
values to fall (11). Elevated homocysteine favors motor neuron 
degeneration (12), and depressed cysteine favors glutathione 
deficiency, hence greater susceptibility to motor neuron degen-
eration (13). When the antioxidant glutathione becomes less 
available, reserves of the antioxidant, vitamin E, will be drawn 
upon. Physiological differences among sheep, horses, and 
humans in the way they process purines and sulfur amino acids, 
render sheep and humans susceptible to purine loading, but not 
horses, and horses and humans susceptible to sulfite loading, but 
not sheep. Purine loading occurs in species that both salvage and 
excrete purines, namely, sheep and humans. It does not occur in 
species that only excrete purines, namely, dogs, cattle, rats, and 
mice. Hence, it is necessary to use a sheep model rather than a 
mouse model for these studies. Likewise, sulfite loading occurs 
in mongastric species, such as humans and horses, but not in 
ruminant species, such as sheep and cattle; hence, sheep are an 
unsuitable model for studies of this kind.
The author proposes that Mo deficiency in humans makes 
them susceptible to the potential neurotoxic effects of dietary 
xanthosine, inosine, and sulfur amino acids, and it is the com-
bined effect of these three substances that produces SC-ALS. The 
following circumstantial evidence supports the notion that a large 
number of humans are Mo deficient, hence, at risk of this disease. 
The daily Mo intake per person in the US is 0.18 mg (14) and in 
the UK is 0.11 mg (15). If daily food intake is 3% of body weight 
and the average body weight is 83  kg, then the Mo content of 
the average US diet would be 0.07 ppm, and the average UK diet 
0.04 ppm. By comparison, Mo deficiency is known to produce 
motor nervous disease in sheep when the Mo content of the 
diet is <0.04 ppm (range <0.01–0.20) (2). On this basis, a large 
number of US and UK citizens are Mo deficient. In the US, the 
incidence of ALS is 1.87 per 100,000 (16) and in the UK it is 3.25 
per 100,000 (17). The prevalence figures for each country also 
reflect this difference, approaching 4 per 100,000 in the US and 
7 per 100,000 in the UK. The 61% lower Mo intake in the UK 
is therefore associated with a 74% higher incidence of ALS, and 
this is consistent with Mo deficiency predisposing to ALS. The 
low blood urate levels commonly recorded for patients with ALS 
offers further support for this opinion (18). Low blood urate levels 
are indicative of low xanthine oxidase activity, and low xanthine 
oxidase activity is caused by Mo deficiency.
One final aspect of Mo deficiency requires some comment. Mo 
deficiency can potentially produce both astrocyte degeneration 
and neuron degeneration. The contribution that neuron degen-
eration makes to the pathogenesis of SC-ALS is universally agreed 
upon; however, there is also an emerging awareness of the potential 
contribution of astrocyte degeneration to this disease (19). Both 
XMNS and IMNS have demonstrated that astrocyte degeneration 
can generate progressive and irreversible motor nervous effects 
and that this process involves a very long preclinical latent period. 
It is possible that SC-ALS also involves a very long preclinical 
latent period, which would be consistent with its normal age of 
onset of >55 years, and that astrocyte degeneration plays a part 
in this. In the subset of ALS that occurs on the Pacific island of 
Guam, it has been possible to follow individuals who have left 
Guam without clinical disease, not returned, and then gone on 
to develop ALS. From two such studies, the period between 
leaving Guam and developing ALS has been determined to be 
1–34 years with a mean of 14 years (20, 21). Sheep studies have 
demonstrated that Mo deficiency precipitated motor nervous 
effects develop after a mean preclinical latent period of 2 years. 
Assuming a life expectancy of 91 years for humans and 13 years 
for sheep, the 2-year mean latent period in sheep would equate 
to 14 human years. Considering that the causal agent is already 
loaded by the time the preclinical latent period commences, it is 
difficult to accept that neuronal degeneration starts on day 1 of 
the latent period and yet clinical effects do not appear for another 
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14 years. It would make more sense if a more subtle process such as 
astrocyte degeneration was initiated on day 1 of the latent period 
and neuronal degeneration not until many years after that day.
There is an accumulation of evidence suggesting that some 
sporadic cases of ALS are at least partly due to genetic mutations 
(22). In the light of this evidence, it is possible that rather than 
Mo deficiency in isolation being the cause of SC-ALS it could be 
that Mo deficiency is the environmental factor that leads to the 
complete disease in persons of a particular genotype.
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